Compared to EGFR-TKIs alone, EGFR-TKIs combined with chemotherapy improved ORR and mPFS in advanced lung adenocarcinoma with EGFR 19Del, L858R mutation. This evidence concerns the gene EGFR and lung adenocarcinoma.